Menstrual products have long been assumed safe from an endocrine standpoint, yet the vaginal mucosa is among the most absorptive tissues in the body — making chemical leaching from tampons a biologically plausible concern that has received surprisingly little regulatory scrutiny. This study shifts that assumption, finding measurable estrogenic bioactivity in a substantial fraction of commercially available products.
Researchers tested 18 tampon brands — spanning both synthetic and certified-organic cotton varieties sourced from domestic and international markets — using a cell-based estrogen receptor (ER) reporter bioassay. Estrogenic activity was detected in roughly 9 of the 18 brands, with no clear pattern tied to material type, meaning organic certification did not confer protection. High-resolution mass spectrometry comparing one estrogenic-active brand against one inactive brand tentatively identified elevated concentrations of plasticizers, surfactants, and fragrance agents in the active product — including known endocrine disruptors such as phthalates and alkylphenols. Critically, the estrogenic signal varied by brand, pointing to formulation-specific risk rather than a category-wide hazard.
The findings sit at the intersection of two under-studied areas: cumulative low-dose EDC exposure and the specific pharmacokinetics of vaginally absorbed compounds. The vaginal epithelium bypasses first-pass hepatic metabolism, meaning compounds absorbed transvaginally may reach systemic circulation more efficiently than the same compounds ingested orally — a pharmacological nuance that makes in vitro bioactivity levels harder to dismiss. The detected activity was low in absolute terms, and the study does not establish human harm; it is an in vitro screening exercise, not a clinical or epidemiological study. Nonetheless, the methodology — bioassay-guided chemical identification — represents a more functionally meaningful approach than ingredient-list audits alone. Regulatory frameworks for menstrual products in most jurisdictions still do not mandate endocrine bioactivity testing, and this work makes a data-grounded case for closing that gap. The finding is incremental but directionally important.